Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EVO756, Dose 1
EVO756 · 3 trials · 3 indications
Safety will be assessed by the total number of subjects with at least one TEAE
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | Orally administered EVO756, Dose 1 |
| Dose 2 | EXPERIMENTAL | Orally administered EVO756, Dose 2 |
| Dose 3 | EXPERIMENTAL | Orally administered EVO756, Dose 3 |
| Placebo | PLACEBO_COMPARATOR | Placebo control |
| Placebo control | PLACEBO_COMPARATOR | Orally administered placebo control |
| EVO756 300 mg QD | EXPERIMENTAL | Oral EVO756 300 mg QD |
| EVO756 50 mg BID | EXPERIMENTAL | Oral EVO756 50 mg BID |
| Name | Type | Description |
|---|---|---|
| EVO756 | DRUG | Dose 1 |
| Placebo control | DRUG | Placebo control |
| Oral EVO756 300 mg QD | DRUG | Oral EVO756, 300 mg once daily |
| Oral EVO756 50 mg BID | DRUG | Oral EVO756 50 mg twice daily |
Inclusion Criteria: * Chronic AD that has been present for ≥6 months * Validated-Investigator's Global Assessment score of ≥3 * EASI of ≥16 * BSA of AD involvement of ≥10% Exclusion Criteria: * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, o...
EVO756 is an investigational small molecule being developed for chronic spontaneous urticaria, chronic inducible urticaria, migraine, and atopic dermatitis. It is currently in Phase 2 clinical trials for these conditions.
EVO756 targets MRGPRX2, a receptor involved in mast cell activation. By modulating this receptor, EVO756 aims to address pathways relevant to conditions like chronic urticaria and atopic dermatitis.
EVO756 is being developed by Evommune, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol EVMN.
EVO756 is in Phase 2 clinical development. It is not yet approved by regulatory authorities and remains an investigational drug being studied for multiple indications.
EVO756 is being studied in several Phase 2 trials, including NCT06603220 for chronic inducible urticaria, NCT06873516 for chronic spontaneous urticaria, NCT07150845 for atopic dermatitis, and NCT07616128 for migraine.
Yes, EVO756 is also known as Dose 1. This alternative name may be used in certain contexts, but both refer to the same investigational drug developed by Evommune, Inc.